Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Becton, Dickinson and Company
Becton, Dickinson and Company News
Becton, Dickinson and Company Quantitative Score
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Becton, Dickinson and Company Earnings & Revenue
Becton, Dickinson and Company Financials
Table Compare
Compare BDX metrics with: | |||
---|---|---|---|
Earnings & Growth | BDX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BDX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BDX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BDX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Becton, Dickinson and Company Income
Becton, Dickinson and Company Balance Sheet
Becton, Dickinson and Company Cash Flow
Becton, Dickinson and Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Neutral |
Return on Assets | Buy |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Sell |
Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Becton, Dickinson and Company Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 3.8000 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-09-30 | 0.95 | Quarterly |
2024-06-28 | 0.95 | Quarterly |
2024-03-29 | 0.95 | Quarterly |
2023-12-29 | 0.95 | Quarterly |
Becton, Dickinson and Company Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Becton, Dickinson and Company Executives
Name | Role |
---|---|
Mr. Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman |
Ms. Shana Carol Neal | Executive Vice President & Chief People Officer |
Mr. Michael Garrison | Executive Vice President & President of Medical segment |
Mr. Christopher J. DelOrefice | Executive Vice President & Chief Financial Officer |
Ms. Denise Russell Fleming | Executive Vice President of Technology & Global Services and Chief Information Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman | Male | 1973 | 3.46M |
Ms. Shana Carol Neal | Executive Vice President & Chief People Officer | Female | 1966 | 1.79M |
Mr. Michael Garrison | Executive Vice President & President of Medical segment | Male | 1970 | 1.73M |
Mr. Christopher J. DelOrefice | Executive Vice President & Chief Financial Officer | Male | 1971 | 1.6M |
Ms. Denise Russell Fleming | Executive Vice President of Technology & Global Services and Chief Information Officer | Female | 1970 | -- |
Becton, Dickinson and Company Insider Trades
Date | 7 Sep |
Name | DelOrefice Christopher |
Role | EVP & Chief Financial Officer |
Transaction | Disposed |
Type | F-InKind |
Shares | 466 |
Date | 1 Sep |
Name | Byrd Richard |
Role | EVP & President Interventional |
Transaction | Disposed |
Type | F-InKind |
Shares | 216 |
Date | 1 Sep |
Name | DelOrefice Christopher |
Role | EVP & Chief Financial Officer |
Transaction | Disposed |
Type | F-InKind |
Shares | 254 |
Date | 20 Aug |
Name | Feld Michael |
Role | EVP & President, Life Sciences |
Transaction | Acquired |
Type | A-Award |
Shares | 6637 |
Date | 20 Aug |
Name | Feld Michael |
Role | EVP & President, Life Sciences |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
7 Sep | DelOrefice Christopher | EVP & Chief Financial Officer | Disposed | F-InKind | 466 |
1 Sep | Byrd Richard | EVP & President Interventional | Disposed | F-InKind | 216 |
1 Sep | DelOrefice Christopher | EVP & Chief Financial Officer | Disposed | F-InKind | 254 |
20 Aug | Feld Michael | EVP & President, Life Sciences | Acquired | A-Award | 6637 |
20 Aug | Feld Michael | EVP & President, Life Sciences | Disposed | 0 |